FULC Fulcrum Therapeutics Inc

Price (delayed)

$8.93

Market cap

$555.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.6

Enterprise value

$524.02M

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine ...

Highlights
The company's EPS rose by 28% YoY
The debt has contracted by 21% YoY and by 6% from the previous quarter
Fulcrum Therapeutics's quick ratio has increased by 15% from the previous quarter but it has decreased by 3.4% YoY
Fulcrum Therapeutics's net income has increased by 9% YoY but it has decreased by 2.1% from the previous quarter
Fulcrum Therapeutics's gross profit has decreased by 38% YoY and by 11% from the previous quarter
The revenue has contracted by 38% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of FULC
Market
Shares outstanding
62.15M
Market cap
$555.03M
Enterprise value
$524.02M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.59
Price to sales (P/S)
220.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
208.77
Earnings
Revenue
$2.51M
EBIT
-$99.43M
EBITDA
-$97.34M
Free cash flow
-$92.5M
Per share
EPS
-$1.6
Free cash flow per share
-$1.49
Book value per share
$3.45
Revenue per share
$0.04
TBVPS
$3.75
Balance sheet
Total assets
$232.59M
Total liabilities
$19M
Debt
$10.14M
Equity
$213.59M
Working capital
$207.26M
Liquidity
Debt to equity
0.05
Current ratio
20.38
Quick ratio
20.06
Net debt/EBITDA
0.32
Margins
EBITDA margin
-3,878.1%
Gross margin
100%
Net margin
-3,961.2%
Operating margin
-4,484.4%
Efficiency
Return on assets
-37.2%
Return on equity
-40.6%
Return on invested capital
-42.9%
Return on capital employed
-44.8%
Return on sales
-3,961.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FULC stock price

How has the Fulcrum Therapeutics stock price performed over time
Intraday
3.84%
1 week
3.12%
1 month
33.68%
1 year
131.95%
YTD
32.3%
QTD
44.03%

Financial performance

How have Fulcrum Therapeutics's revenue and profit performed over time
Revenue
$2.51M
Gross profit
$2.51M
Operating income
-$112.56M
Net income
-$99.43M
Gross margin
100%
Net margin
-3,961.2%
Fulcrum Therapeutics's operating margin has plunged by 58% YoY and by 14% from the previous quarter
The net margin has contracted by 47% YoY and by 14% from the previous quarter
Fulcrum Therapeutics's gross profit has decreased by 38% YoY and by 11% from the previous quarter
The revenue has contracted by 38% YoY and by 11% from the previous quarter

Growth

What is Fulcrum Therapeutics's growth rate over time

Valuation

What is Fulcrum Therapeutics stock price valuation
P/E
N/A
P/B
2.59
P/S
220.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
208.77
The company's EPS rose by 28% YoY
FULC's P/B is 56% above its last 4 quarters average of 1.6 but 4.2% below its 5-year quarterly average of 2.6
The equity has contracted by 28% YoY and by 9% from the previous quarter
The price to sales (P/S) is 142% higher than the 5-year quarterly average of 87.8 and 54% higher than the last 4 quarters average of 138.1
The revenue has contracted by 38% YoY and by 11% from the previous quarter

Efficiency

How efficient is Fulcrum Therapeutics business performance
The company's return on sales fell by 47% YoY and by 14% QoQ
FULC's return on invested capital is up by 24% year-on-year but it is down by 12% since the previous quarter
Fulcrum Therapeutics's ROE has increased by 18% YoY but it has decreased by 11% from the previous quarter
Fulcrum Therapeutics's ROA has increased by 15% YoY but it has decreased by 11% from the previous quarter

Dividends

What is FULC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FULC.

Financial health

How did Fulcrum Therapeutics financials performed over time
FULC's total assets is down by 28% year-on-year and by 10% since the previous quarter
Fulcrum Therapeutics's total liabilities has decreased by 24% YoY and by 16% from the previous quarter
The debt is 95% less than the equity
The equity has contracted by 28% YoY and by 9% from the previous quarter
The debt to equity is up by 25% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.